ClinicalTrials.gg
CompletedNCT05993884Updated Aug 12, 2025

Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke

A Phase 1 interventional study of iEPCs and Placebo in Acute Ischemic Stroke, sponsored by Allife Medical Science and Technology Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Allife Medical Science and Technology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Enrollment
533rd of 566
27 · median 271
Started
2023
with 91 others
Phase 1
28 of 754
10 open now
Registered
352nd of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 533rd largest by enrollment of the 566 interventional ones that give a count, is one of 92 that started in 2023, is one of 28 in phase 1, and was the 352nd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, dose-Escalation clinical study to investigate the safety and efficacy of EPCs transplantation in Acute ischemic stroke.

Read the detailed description

Acute ischemic stroke (AIS) occurs when blood flow to the brain is blocked by a clot or mechanical event and is the most common type of stroke. However, due to the limitation of time and contraindications, only a few patients with AIS are eligible candidates. Endothelial progenitor cells (EPCs) have the potential to reduce brain damage from AIS. They can effectively repair endothelial cells with vascular injuries by directly differentiating into endothelial cells or releasing corresponding regulatory factors, which is a potentially important means for the prevention and treatment of a series of vascular system disorders. The introduction of induced pluripotent stem cells (iPSCs) technology provides a highly feasible option for clinical application of EPCs. Allogeneic iPSC-EPCs can be produced on a large scale to provide enough cells, fundamentally solving the problem of insufficient dosage, and making them a feasible clinical option for treatment of AIS.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • EPCs
  • phase Ⅰ
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Able to provide consent to study or consent is obtained from the patient's legal representative
  • 2.Male or females,aged 18 to 80 years
  • 3. Subjects with acute ischemic stroke:1) Onset time ≤ 7 days; 2) Imaging confirmed infarction in the blood-supplying area of the internal carotid artery; 3) treated with thrombolysis and/or thrombolysis, or without the above treatment;
  • 4.Subjects with NIHSS score between≥6 points and≤24 points at the time of screening
  • 5.Eligible patients of (both men and women)if sexually active must agree to use a reliable method of with their partners

Exclusion criteria

Exclusion Criteria:

  1. Impaired consciousness (NIHSS score Ia ≥ 2);
  2. Disease progression or fluctuation in the subject after the first visit to the screening enrollment, which in the judgment of the investigator has a poor prognosis and will not benefit from this clinical study;
  3. Those who have bleeding conversion as assessed by imaging after thrombolysis and/or thrombolysis;
  4. History of previous intracranial hemorrhage (within 1 year), arteriovenous malformations, arterial entrapment, aneurysm (≥3 mm in maximum diameter), epilepsy, and history of brain tumor;
  5. Abnormalities in major organ function

7. severe respiratory disease that, as assessed by the investigator, may have an impact on the subject's determination of test results (active tuberculosis, , interstitial lung disease, severe or critical pneumonia); 8. Uncontrolled hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg) after treatment, which in the judgment of the investigator carries a high risk of bleeding and has a poor prognosis; 9. Those with malignant tumors or a history of malignant tumors; 10. Have an disease or are undergoing immunotherapy; 11. Being pregnant or breastfeeding; 12. Allergic to multiple drugs (≥2) or allergic to human albumin; 13. have been alcohol- or drug-dependent in the 6 months prior to the onset of illness or have had an episode of acute alcoholism in the 24 h prior to the onset of illness or have had an episode of Those with acute alcohol intoxication within 24 h; 14. History of psychiatric illness or severe cognitive impairment that may affect the evaluation of neurologic function; 15. Positive for surface antigen, positive for virus antibody, positive for syphilis serum antibody or positive for antibody; 16. Being enrolled in a clinical study of another drug; 17. Patients who, in the opinion of the investigator, are not suitable for participation in this study.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Experimental: Cohort 1

    1X level dose of iEPCs

    Drug: iEPCs

  • Experimental
    Experimental: Cohort 2

    3X level dose of iEPCs or placebo

    Drug: iEPCs · Drug: Placebo

  • Experimental
    Experimental: Cohort 3

    6X level dose iEPCs or Placebo

    Drug: iEPCs · Drug: Placebo

  • Experimental
    Experimental: Cohort 4

    10X level dose of iEPCs or placebo

    Drug: iEPCs · Drug: Placebo

Interventions

  • DrugiEPCs

    Patients receive iEPCs IV with the single dose

    Also known as: iPSC EPCs

  • DrugPlacebo

    Patients receive placebo IV with a single dose

    Also known as: iEPCs excipients

06

What researchers measure

Primary outcomes

  1. Evaluate the Incidence and severity of adverse events after iEPCs infusion

    Incidence and severity of adverse events assessed by CTCAE V5.0 during the twelve-month study period after iEPCs infusion.

    Time frame: baseline to 1 year

Other outcomes

  1. HLA matching

    the level of HLA matching pairs of donor/recipient

    Time frame: From enrollment to the end of treatment at 1 year

  2. plasma HLA antibody

    The change from the baseline of plasma HLA antibody will be calculated at Day 14,month 1, month 3 post infusion, as available.

    Time frame: From enrollment to the end of treatment at 14 days, 1 month and 3 months

  3. plasma T lymphocytes

    The change from the baseline in plasma T lymphocytes will be calculated at day 1, day 3, day 7, day 14, day 21, month 1, month 3, month 6, month 9, month 12 post infusion, as available.

    Time frame: From enrollment to the end of treatment at 1 day , 3 days, 7 days, 14 days, 21 days, 1 month , 3 months, 6 months, 9 months, 12 months

  4. plasma iEPCs

    The change from the baseline in plasma iEPCs will be calculated at 30\~40 min, day 1, day 3, day 7, day 14, day 21, month 1, month 2, month 3 post infusion, as available.

    Time frame: From enrollment to the end of treatment at 30~40 mins, 1 day, 3 days, 7 days, 14 days, 21 days, 1 month, 2 months, 3 months

  5. Modified Rankin Scale, mRS

    The change from the baseline in mRS will be calculated at month 1, month 3, month 6, as available. The scale is divided into 7 degrees, from 0 (no deficit) to 6 (dead).

    Time frame: From enrollment to the end of treatment at 1 month, 3 months, 6 months

  6. National Institute of Health stroke scale, NIHSS

    The change from the baseline in NIHSS will be calculated at month 1, month 3, month 6 post-treatment, as available. The range of scores is from 0 (normal) to 42.

    Time frame: From enrollment to the end of treatment at 1 month, 3 months, 6 months

  7. activity of daily living, ADL

    The change from the baseline in ADL will be calculated at month 1, month 3, month 6 post-treatment, as available. Every activity will be scored 5 and the range of scores is from 0 (normal) to 5.

    Time frame: From enrollment to the end of treatment at 1 month, 3 months, 6 months

  8. cerebral infarct volume

    The change from baseline in cerebral infarct volume using MRI will be calculated at day 7, month 6 post-treatment, as available.

    Time frame: From enrollment to the end of treatment at 7 days and 6 months

  9. vascular endothelial growth factor, VEGF

    Changes of concentration of vascular endothelial growth factor(VEGF)in the serum from the baseline will be calculated at day 1, day 3, day 7, day 14, day 21, month 1, month 3, month 6, month 9, month 12 post-treatment, as available.

    Time frame: From enrollment to the end of treatment at 1 day , 3 days, 7 days, 14 days, 21 days, 1 month , 3 months, 6 months, 9 months, 12 months

  10. brain derived neurotrophic factor,BDNF

    Changes of concentration of brain derived neurotrophic factor (BDNF) in the serum from the baseline will be calculated at day 1, day 3, day 7, day 14, day 21, month 1, month 3, month 6, month 9, month 12 post-treatment, as available.

    Time frame: From enrollment to the end of treatment at 1 day , 3 days, 7 days, 14 days, 21 days, 1 month , 3 months, 6 months, 9 months, 12 months

07

Study locations

2 sites
  • Allife Medicine (Beijing) Limitied
    Beijing, Beijing Municipality 100053, China
  • Allife
    Beijing, Beijing Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2025, 19 months.

Of 42 phase 1 interventional studies under Ischemic Stroke, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
Aug 15, 2023
StartActual
Aug 24, 2023
Primary completionActual
Apr 15, 2025
CompletionActual
Apr 15, 2025
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05993884
Lead sponsor
Allife Medical Science and Technology Co., Ltd.
Collaborators
Linfen Central Hospital, Peking University Third Hospital, Xuanwu Hospital, Beijing, Beijing Tiantan Hospital, Linyi People's Hospital
Responsible party
Sponsor
First posted
Aug 15, 2023
Start date
Aug 24, 2023
Primary completion
Apr 15, 2025
Completion
Apr 15, 2025
Last update
Aug 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion